Background

The EMA has approved Qdenga (live‑attenuated vaccine). The vaccine is tetravalent, designed to target all four dengue virus serotypes. Clinical trials demonstrated favorable safety and immunogenicity, leading to approval. The approval was confirmed on 5 December 2022.

Competitive Landscape

The dengue vaccine market currently includes products such as Dengvaxia (Sanofi), which have been limited by age restrictions and safety concerns. Qdenga differentiates itself by covering a broader age range and offering an improved safety profile compared with earlier vaccines. This provides a new option in a market where demand for existing vaccines has been constrained.

Reimbursement and Market Entry Challenges

In Europe, national health authorities make separate reimbursement decisions, requiring country‑specific health policy alignment and pricing negotiations. Moreover, because dengue is primarily endemic to tropical and subtropical regions, actual demand within Europe may be limited. Consequently, manufacturers must design a cautious initial market entry strategy.

Market Size Outlook

Although the source does not provide a specific market‑size estimate, the WHO reports more than 3.9 million dengue infections annually, suggesting substantial long‑term global growth potential. Expansion in endemic tropical regions and increasing demand for traveler protection in Europe are expected to drive future market expansion.